Loading company…
VitriVax develops vaccine formulation technology, including its thermostable formulation platform ALTA.
Founded in 2017 and based in Boulder, US, VitriVax develops vaccination technology. In October 2025, it raised USD 17.25 million in Series B funding co-led by Adjuvant Capital and RA Capital Management. The company plans to use the funding to develop and commercialize its thermostable vaccine formulation technology, ALTA.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in